Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Worth noting from the Canaccord note that the $8.5m EDITDA figure is based on $60/kg. Current price is approx. $66 and according to SQM (who are really the price setters) have said they expect stable prices this year.
As long as you can be patient you will be rewarded. Completely under the radar.
Doesn’t seem too much stock around at the moment which bodes well if we have continued positive data and/or another licensing deal.
Comment below I posted on ADVFN. 2nd largest producer Cosayach had the extension of a large mine rejected earlier this week…
A little more digging on the Cosayach Negreiros mine.
At best production will start to tail off next year. I think it currently produces around 2000t a year so over 5% of world production.
The article below confirms they will have to start laying people off in the coming months.
This is the 3rd time in 3 years the application has been rejected. They can appeal and resubmit but you would think it will take at least another 6 months to reverse any decision.
You would think in current situation Cosayach will hold back some iodine sales to create a buffer in case they lose 1/3rd of their production next year.
Spot iodine price fell around 9% from its peak but has rallied 2% in last few days.
I think this is very significant news and could well keep the Iodine price higher for longer.
“However, it again suffered the anticipated term of its processing, again due to the consideration of the authority that there was a lack of essential information to evaluate the possible impacts of the activities, for example, on human groups belonging to indigenous peoples indicated in the area of influence. In a statement issued this Wednesday by Cosayach, the mining company lamented "the decision of the government authority that recommends rejecting" its initiative, and expressed its concern that "an administrative decision jeopardises the employment of more than a thousand workers." In it, they affirm that during the following months, the Negreiros task "will exhaust the mine area authorised environmentally for the extraction of caliche so operations will cease and contracted personnel must be demobilised."
FastMarkets try and track it but mainly you have to follow what SQM say.
Price is in late 60’s and fairly stable although most analysts expect it to average $60 for 2024.
It would become a combination therapy resetting patent life.
They have all the tools to do that but SCLP had indicated that the trials were going well and they would be presenting papers this week.
Quite a few people will have bought on speculation and for once were right to.
It’s only showing less than 1m shares traded which is small although probably some delayed trades to go through.
Whilst the fact is EU and Europe generally needs to produce more metals and oil due the geopolitical situation I worry that the wokesters will hinder projects.
I use the World leading Salamander uranium project as an example.
It’s all about being able to extend patent life via combination therapies. The Keytruda patent expires in 2028 and Merck don’t want to give up $25bn of revenue per year.
Well worth a read on the AR to understand what they do.
https://crimsontide.co.uk/wp-content/uploads/2023/05/Annual-Reports-and-Accounts-2022.pdf
Hopefully it is a hidden gem. Growing at 25-30% per year. P/E of 10 for next years. High margin, low churn rate. Cash of £3m.
Management own a lot, relatively low salaries and have sold businesses before.
It’s all about communication. In this case Ichor just placed an order through a market maker and were prepared to take a price lower than the market.
Often when options expire the Company,seller and company broker will work together to find a buyer to try and reduce market volatility. Often in a more illiquid stock it can be a good opportunity for a new fund to get a position.
Why? With biotech shares this type of volatility is entirely normal. Make sure you only invest what you are prepared to lose.
It is perfectly normal for such volatility in biotech stocks-that is the name of the game. High risk, high reward. Having said that, especially as the news is so good, the company should have a plan on how to deal with blocks of stock such as those from the options. Back in 2021 Lindy found a biotech analyst to take her options at 20p but nothing was done here. Anyway looks like they are probably out now.
My opinion is the Company have leading edge technology but have completely failed in the last few months to expand the shareholder base.
Barely anyone has heard of Scancell let alone know what they do.
In many ways I like the way they prefer to be under the radar but living under a stone isn’t the answer either.
They should not be focusing too much on the retail investors-sorry-although there should be quarterly proactive investor type interviews.
The main focus should be seeing specialist biotech funds and Family offices not only in the UK but US, Switzerland and Singapore. There are plenty of wealthy philanthropists out there who want to back new cancer treatments.
They need to get out there and tell people what they are doing.
Not all 23 patients will of had their 8 week scans imo.
Emptyend,
$24k is just for the terminal itself and as you will know you also have the market access/exchange fees on top so it all adds up quite quickly but yes the base fee doesn’t seem to have changed for 20 years.
Yes the shareholder data came off Bloomberg too although you can pay around £500 to get a detailed share register as a one off from Argus Vickers.
If you ask a broker who uses a Bloomberg terminal (subscription $24k per annum) to look up SCLP news they will confirm there was a scheduled roadshow. It’s not made up!
It’s perfectly normal to see shareholders and potential shareholders after results. Potential new funds generally have to do their own dd and go through investment committees before buying shares.
AB if that is what some thought then they are completely clueless! A 10 or 20% patient response would be amazing considering all patients have had no response to the standard of care treatments.
Better off having uneducated investors out tbh.
Getting a response on 2 ovarian cancer patients including one from the low dosage first cohort far outweighs any news on Covidity.
Covidity is bottom of the list-they wouldn’t have done it if the hadn’t have got the Govt grant.